Modulation of phenotypic expression of APOA5 Q97X and L242P mutations

Atherosclerosis

Volumn 207, Issue 1, 2009, Pages 150-156

  Charriere S ^a,b,c,d   Cugnet, C ^d   Guitard, M ^d   Bernard, S ^a,b,c,d   Groisne, L ^d   Charcosset, M ^d   Pruneta Deloche, V ^a,b,c   Merlin, M ^e   Billon, S ^e   Delay, M ^e   Sassolas, A ^d   Moulin, P ^a,b,c,d   Marcais C ^a,b,c,e  

^a UNIVERSITÉ LYON 1   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE LYON   (France)

^d LOUIS PRADEL HOSPITAL   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

APOA5; Hyperchylomicronemia; Hypertriglyceridemia; Mutation; Type V hyperlipidemia

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN C2; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLUTAMINE; LEUCINE; LIPOPROTEIN LIPASE; PROLINE; ROSUVASTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DIET THERAPY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HAPLOTYPE; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HYPERLIPOPROTEINEMIA TYPE 1; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; APOLIPOPROTEIN C-III; APOLIPOPROTEINS A; APOLIPOPROTEINS E; BLOTTING, WESTERN; CHILD; DIABETES MELLITUS, TYPE 2; DNA MUTATIONAL ANALYSIS; FEMALE; HAPLOTYPES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; INSULIN RESISTANCE; LIPOLYSIS; LIPOPROTEIN LIPASE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MUTATION; PHENOTYPE;

EID: 70350759426     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.04.021     Document Type: Article

References (40)

1. Brunzell J.D. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic and molecular bases of inherited disease. 7th ed. vol. 2 (1995), McGraw-Hill, New York 1913-1932
2. Merkel M., Eckel R.H., and Goldberg I.J. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43 (2002) 1997-2006
3. Gregg R.E., Zech L.A., and Brewer H.B. Apolipoprotein E alleles in severe hypertriglyceridaemia. Lancet 1 (1983) 353
4. Talmud P.J., and Humphries S.E. Apolipoprotein C-III gene variation and dyslipidaemia. Curr Opin Lipidol 8 (1997) 154-158
5. Marçais C., Bernard S., Merlin M., et al. Severe hypertriglyceridemia in type-II diabetes: involvement of Apo C-III Sst-I polymorphism, LPL mutations and Apo E3 deficiency. Diabetologia 43 (2000) 1346-1352
6. Wang J., Cao H., Ban M.R., et al. Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol 27 (2007) 2450-2455
7. Pennacchio L.A., Olivier M., Hubacek J.A., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001) 169-173
8. Pennacchio L.A., Olivier M., Hubacek J.A., et al. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 11 (2002) 3031-3038
9. Talmud P.J., Hawe E., Martin S., et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 11 (2002) 3039-3046
10. Olivier M., Wang X., Cole R., et al. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 83 (2004) 912-923
11. Merkel M., Loeffler B., Kluger M., et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280 (2005) 21553-21560
12. Marçais C., Verges B., Charrière S., et al. APOA5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 115 (2005) 2862-2869
13. Priore Oliva C.P., Pisciotta L., Li Volti G., et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 25 (2005) 411-417
14. Priore Oliva C., Tarugi P., Calandra S., et al. A novel sequence variant in APOA5 gene found in patients with severe hypertriglyceridemia. Atherosclerosis 188 (2006) 215-217
15. Priore Oliva C., Carubbi F., Schaap F.G., Bertolini S., and Calandra S. Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene. J Intern Med 263 (2008) 450-458
16. Dorfmeister B., Zeng W.W., Dichlberger A., et al. Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler Thromb Vasc Biol 28 (2008) 1866-1871
17. Sunyaev S., Ramensky V., Koch I., et al. Prediction of deleterious human alleles. Hum Mol Genet 10 (2001) 591-597
18. Ng P.C., and Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31 (2003) 3812-3814
19. Thomas P.D., Kejariwal A., Guo N., et al. Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res 34 (2006) W645-W650
20. Genuth S., Alberti K.G., Bennett P., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160-3167
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
22. Haffner S.M., Kennedy E., Gonzalez C., Stern M.P., and Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 19 (1996) 1138-1141
23. Schaap F.G., Nierman M.C., Berbée J.F., et al. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J Lipid Res 47 (2006) 2333-2339
24. Sun G., Bi N., Li G., et al. Identification of lipid binding and lipoprotein lipase activation domains of human apoAV. Chem Phys Lipids 143 (2006) 22-28
25. Lookene A., Beckstead J.A., Nilsson S., Olivecrona G., and Ryan R.O. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem 280 (2005) 25383-25387
26. Weinberg R.B., Cook V.R., Beckstead J.A., et al. Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 278 (2003) 34438-34444
27. Sharp R.J., Perugini M.A., Marcovina S.M., and McCormick S.P. Structural features of apolipoprotein B synthetic peptides that inhibit lipoprotein(a) assembly. J Lipid Res 45 (2004) 2227-2234
28. Lam C.W., Yuen Y.P., Cheng W.F., Chan Y.W., and Tong S.F. Missense mutation Leu72Pro located on the carboxyl terminal amphipathic helix of apolipoprotein C-II causes familial chylomicronemia syndrome. Clin Chim Acta 364 (2006) 256-259
29. Charriere S., Bernard S., Aqallal M., et al. Association of APOA5-1131T>C and S19W gene polymorphisms with both mild hypertriglyceridemia and hyperchylomicronemia in type 2 diabetic patients. Clin Chim Acta 394 (2008) 99-103
30. Eichenbaum-Voline S., Olivier M., Jones E.L., et al. Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 24 (2004) 167-174
31. Wang J., Ban M.R., Kennedy B.A., et al. APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med 5 (2008) 730-737
32. Talmud P.J., Palmen J., Putt W., Lins L., and Humphries S.E. Determination of the functionality of common APOA5 polymorphisms. J Biol Chem 280 (2005) 28215-28220
33. Palmen J., Smith A.J., Dorfmeister B., et al. The functional interaction on in vitro gene expression of APOA5 SNPs, defining haplotype APOA5*2, and their paradoxical association with plasma triglyceride but not plasma apoAV levels. Biochim Biophys Acta 1782 (2008) 447-452
34. Vaessen S.F., Schaap F.G., Kuivenhoven J.A., et al. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J Lipid Res 47 (2006) 2064-2070
35. Ahituv N., Akiyama J., Chapman-Helleboid A., et al. In vivo characterization of human APOA5 haplotypes. Genomics 90 (2007) 674-679
36. Talmud P.J., Cooper J.A., Hattori H., et al. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia 49 (2006) 2337-2340
37. Henneman P., Schaap F.G., Havekes L.M., et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis 193 (2007) 129-134
38. Evans D., Seedorf U., and Beil F.U. Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia. Clin Genet 68 (2005) 369-372
39. Hubacek J.A., Horínek A., Skodova Z., et al. Hypertriglyceridemia: interaction between APOE and APOAV variants. Clin Chem 51 (2005) 1311-1313
40. Sousa M.O., Alía P., Pintó X., Corbella E., and Navarro M.A. Interaction between APOA5-1131T>C and APOE polymorphisms and their association with severe hypertriglyceridemia. Clin Chim Acta 395 (2008) 68-71